SUPPLEMENTAL INDENTURE
EX-10.309 12 ex-10309supp_indenturex6x0.htm SUPPLEMENTAL INDENTURE 6.00% 2023 NOTES Exhibit
Exhibit 10.309
SUPPLEMENTAL INDENTURE
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of September 30, 2015, among Par Pharmaceutical Companies, Inc., a Delaware corporation, Par Pharmaceutical, Inc., a Delaware corporation, Anchen Incorporated, a Delaware corporation, Par, Inc., a Delaware corporation, Anchen Pharmaceuticals, Inc., a California corporation, JHP Group Holdings, Inc., a Delaware corporation, JHP Acquisition, LLC, a Delaware limited liability company, Par Sterile Products, LLC, a Delaware limited liability company, Kali Laboratories, Inc., a New Jersey corporation, Innoteq, Inc., a Connecticut corporation, Par Laboratories Europe, Ltd., a company organized under the laws of the United Kingdom and Endo Finance IV Limited, a private limited company incorporated under the laws of Ireland (each, a “Guaranteeing Subsidiary” and collectively, the “Guaranteeing Subsidiaries”), subsidiaries of Endo Designated Activity Company, a private limited company incorporated under the laws of Ireland (the “Company”), the Issuers, the other Guarantors (both, as defined in the Indenture referred to below) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).
W I T N E S S E T H
WHEREAS, the Company, Endo Finance LLC, a Delaware limited liability company, and Endo Finco Inc., a Delaware corporation, have heretofore executed and delivered to the Trustee an indenture, dated as of July 9, 2015(the “Indenture”), providing for the issuance of 6.000% Senior Notes due 2023 (the “Notes”);
WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Issuers’ Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”);
WHEREAS, this Supplemental Indenture has not resulted in a material modification of the Notes for Foreign Account Tax Compliance Act purposes; and
WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.
NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:
1.CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.
2.AGREEMENT TO GUARANTEE. Each of the Guaranteeing Subsidiaries hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10 thereof.
3.NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator or stockholder of the Issuers or any Guarantor, as such, will have any liability for any obligations of the Issuers or the Guarantors under the Notes, this Supplemental Indenture, the Note Guarantees
Exhibit 10.309
or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. The waiver may not be effective to waive liabilities under the federal securities laws.
4.NEW YORK LAW TO GOVERN; WAIVER OF JURY TRIAL. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EACH OF THE ISSUERS AND THE GUARANTORS CONSENTS AND IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY NEW YORK STATE OR U.S. FEDERAL COURT LOCATED IN THE BOROUGH OF MANHATTAN, CITY OF NEW YORK, COUNTY OF NEW YORK, STATE OF NEW YORK IN RELATION TO ANY LEGAL ACTION OR PROCEEDING (I) ARISING OUT OF, RELATING TO OR IN CONNECTION WITH THIS INDENTURE, AS SUPPLEMENTED, THE NOTES, THE GUARANTEES AND ANY RELATED DOCUMENTS AND/OR (II) ARISING UNDER ANY U.S. FEDERAL OR U.S. STATE SECURITIES LAWS IN RESPECT OF THE NOTES, THE GUARANTEES AND ANY SECURITIES ISSUED PURSUANT TO THE TERMS OF THE INDENTURE, AS SUPPLEMENTED. EACH OF THE ISSUERS AND THE GUARANTORS WAIVES ANY OBJECTION TO PROCEEDINGS IN ANY SUCH COURTS, WHETHER ON THE GROUND OF VENUE OR ON THE GROUND THAT THE PROCEEDINGS HAVE BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH OF THE GUARANTEEING SUBSIDIARIES, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, SHALL APPOINT CT CORPORATION SYSTEM, 111 EIGHTH AVENUE, 13TH FLOOR, NEW YORK, NY 10011, AS ITS AGENT FOR SERVICE OF PROCESS IN ANY SUCH SUIT, ACTION OR PROCEEDING AND AGREES THAT SERVICE OF PROCESS UPON SAID AUTHORIZED AGENT SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON IT IN ANY SUCH SUIT, ACTION OR PROCEEDING. EACH OF THE GUARANTEEING SUBSIDIARIES AGREES TO DELIVER, UPON THE EXECUTION AND DELIVERY OF THIS SUPPLEMENTAL INDENTURE, A WRITTEN ACCEPTANCE BY SUCH AGENT OF ITS APPOINTMENT AS SUCH AGENT. EACH OF GUARANTEEING SUBSIDIARIES, TO THE EXTENT ORGANIZED OUTSIDE OF THE UNITED STATES, FURTHER AGREES TO TAKE ANY AND ALL ACTION, INCLUDING THE FILING OF ANY AND ALL SUCH DOCUMENTS AND INSTRUMENTS, AS MAY BE REASONABLY NECESSARY TO CONTINUE SUCH DESIGNATION AND APPOINTMENT OF CT CORPORATION SYSTEM IN FULL FORCE AND EFFECT FOR SO LONG AS THE INDENTURE, AS SUPPLEMENTED, REMAINS IN FORCE. EACH OF THE ISSUERS, THE TRUSTEE AND THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY.
5.COUNTERPARTS. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement.
6.EFFECT OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof.
2
Exhibit 10.309
7.THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries and the Issuers.
[Signature Pages Follow]
3
Exhibit 10.309
IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.
PAR PHARMACEUTICAL COMPANIES, INC. | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
PAR PHARMACEUTICAL, INC. | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
ANCHEN INCORPORATED | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
PAR, INC. | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
JHP GROUP HOLDINGS, INC | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
JHP ACQUISITION, LLC | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
PAR STERILE PRODUCTS, LLC | |||
as a Guaranteeing Subsidiary | |||
by JHP ACQUISITION, LLC, as Manager | |||
by JHP GROUP HOLDINGS, INC., its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ANCHEN PHARMACEUTICALS, INC | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
KALI LABORATORIES, INC. | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
INNOTEQ, INC. | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
PAR LABORATORIES EUROPE, LTD | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO FINANC IV LIMITED | |||
as a Guaranteeing Subsidiary | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO FINCO INC. | |||
as an Issuer | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO DESIGNATED ACTIVITY COMPANY | |||
as a Issuer | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO FINANCE LLC | |||
as an Issuer | |||
by ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L., its sole member | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO LLC | |||
ENDO U.S. INC. | |||
each, as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
DAVA PHARMACEUTICALS, INC. | |||
ENDO HEALTH SOLUTIONS, INC. | |||
ENDO PHARMACEUTICALS INC. | |||
ENDO PHARMACEUTICALS SOLUTIONS INC. | |||
ENDO PHARMACEUTICALS VALERA INC. | |||
GENERICS INTERNATIONAL (US PARENT), INC. | |||
GENERICS INTERNATIONAL (US MIDCO), INC. | |||
GENERICS INTERNATIONAL (US HOLDO), INC. | |||
GENERICS INTERNATIONAL (US), INC. | |||
AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.each, as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
GENERICS BIDCO I, LLC | |||
VINTAGE PHARMACEUTICALS, LLC | |||
GENERICS BIDCO II, LLC | |||
MOORES MILL PROPERTIES LLC | |||
WOOD PARK PROPERTIES LLC | |||
QUARTZ SPECIALITY PHARMACEUTICALS, LLC | |||
each as a Guarantor | |||
by GENERICS INTERNATIONAL (US), INC., | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
LEDGEMENT ROYALTY SUB LLC | |||
each as a Guarantor | |||
by ENDO PHARMACEUTICALS SOLUTIONS INC., | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
DAVA International, LLC | |||
as a Guarantor | |||
by DAVA PHARMACEUTICALS, INC., | |||
its sole member | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
DAVA CAPITAL MANAGEMENT, INC. | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
AUXILIUM INTERNATIONAL HOLDINGS, INC. | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
SLATE PHARMACEUTICALS, INC. | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
TIMM MEDICAL TECHNOLOGIES, INC. | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
ACTIENT PHARMACEUTICALS LLC | |||
as a Guarantor | |||
By: AUXILIUM PHARMACEUTICALS, INC., | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ACTIENT THERAPEUTICS LLC | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
AUXILIUM US HOLDINGS, LLC | |||
as a Guarantor | |||
By: AUXILIUM PHARMACEUTICALS, INC., | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
AUXILIUM PHARMACEUTICALS, INC. | |||
as a Guarantor | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
70 MAPLE AVENUE, LLC | |||
as a Guarantor | |||
By: ACTIENT PHARMACEUTICALS LLC, | |||
its manager | |||
By: AUXILIUM PHARMACEUTICALS, INC | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
TIMM MEDICAL HOLDINGS, LLC | |||
its Guarantor | |||
By: ACTIENT PHARMACEUTICALS LLC, | |||
its manager | |||
By: AUXILIUM PHARMACEUTICALS, INC. | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary | ||
APHRODITE WOMEN'S HEALTH, LLC | |||
as a Guarantor | |||
By: AMERICAN MEDICAL SYSTEMS HOLDINGS, INC., | |||
its manager | |||
By: | /s/ | Deanna Voss | |
Name: | Deanna Voss | ||
Title: | Assistant Secretary |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO MANAGEMENT LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director | ||
ENDO VENTURES LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director | ||
ENDO MANAGEMENT II LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director | ||
ENDO FINANCE III LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
HAWK ACQUISITION IRELAND LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director | ||
ENDO TOPFIN LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO IRELAND FINANCE LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
PALADIN LABS CANADIAN HOLDING INC. | |||
as a Guarantor | |||
By: | /s/ | Mark Beaudet | |
Name: | Mark Beaudet | ||
Title: | President | ||
PALADIN LABS INC. | |||
as a Guarantor | |||
By: | /s/ | Mark Beaudet | |
Name: | Mark Beaudet | ||
Title: | President |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO VENTURES BERMUDA LIMITED | |||
as a Guarantor | |||
By: | /s/ | Susan Hall | |
Name: | Susan Hall | ||
Title: | Director | ||
ENDO GLOBAL VENTURES | |||
as a Guarantor | |||
By: | /s/ | Susan Hall | |
Name: | Susan Hall | ||
Title: | Director | ||
HAWK ACQUISITION ULC | |||
as a Guarantor | |||
By: | /s/ | Laurence S. Smith | |
Name: | Laurence S. Smith | ||
Title: | Director | ||
ENDO BERMUDA FINANCE LIMITED | |||
as a Guarantor | |||
By: | /s/ | Robert J. Cobuzzi. | |
Name: | Robert J. Cobuzzi. | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO NETHERLANDS B.V. | |||
as a Guarantor | |||
By: | /s/ | Robert J. Cobuzzi. | |
Name: | Robert J. Cobuzzi. | ||
Title: | Managing Director A | ||
By: | /s/ | Gert Jan Rietberg | |
Name: | Gert Jan Rietberg | ||
Title: | Managing Director B |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO VENTURES CYPRUS LIMITED | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
AUXILIUM UK LTD | |||
as a Guarantor | |||
By: | /s/ | Orla Dunlea | |
Name: | Orla Dunlea | ||
Title: | Director |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO LUXEMBOURG HOLDING COMPANY S.À R.L. | |||
as a Guarantor | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager | ||
ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L. | |||
as a Guarantor | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager | ||
ENDO LUXEMBOURG FINANCE COMPANY II S.À R.L. | |||
as a Guarantor | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
ENDO US HOLDINGS LUXEMBOURG I HOLDING COMPANY S.À R.L. | |||
as a Guarantor | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager | ||
ENDO US HOLDINGS LUXEMBOURG II S.À R.L. | |||
as a Guarantor | |||
By: | /s/ | John D. Boyle | |
Name: | John D. Boyle | ||
Title: | A Manager | ||
By: | /s/ | Joost Tulkens | |
Name: | Joost Tulkens | ||
Title: | B Manager |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]
Exhibit 10.309
WELLS FARGO BANK, NATIONAL ASSOCIATION, | |||
as a Trustee | |||
By: | /s/ | Yana Kislenko | |
Name: | Yana Kislenko | ||
Title: | Vice President |
[Signature Page to 6.000% Notes due 2023 Supplemental Indenture]